Home Studieinformatie Studies open voor inclusie

Acute myeloïde leukemie (AML)

HOVON 150: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy

HOVON 156: A phase 3, multicenter, open-label, randomized study of gilteritinib versus midostaurin in combination with induction and consolidaton therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

NK4AML: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study

Myelodysplastisch syndroom (MDS)

EU-MDS: A prospective, multicentre European registry for newly diagnosed patients with myelodysplastic syndromes (MDS), including acute myeloid leukaemia with 20-30 percent marrow blasts (former RAEB-t), and chronic myelomonocytic leukaemia (CMML)

COMMANDS: A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naïve subjects who require red blood cell transfusions

IMerge 2: A study to evaluate imetelstat (GRN163L) in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment 

Myeloproliferatieve neoplasieën (MPN)

HOVON 134: A phase II trial in patients with myelofibrosis (primary, post-ET or post-PV-MF) treated with the selective JAK2 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation

FREEDOM 2: A phase III, multi center, open-lable, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycytemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib - Inclusie tijdelijk on hold -

TRANSFORM-1: A randomized, double-blind, placebo-controlled, phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib in subjects with myelofibrosis

Hodgkin lymfoom (HL)

COBRA: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study

Non Hodgkin lymfomen (NHL)

HOVON 127: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

HOVON 136: Phase I-II study combining brentuximab vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation

HOVON 152: A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements

LUPIAE: Towards personalized medicine for refractory/relapsed folliculair lymphoma patients: the Cantera/Lupiae registry

Auto-immuun hemolytische anemie (AIHA)

DRAIHA: Data registry of autoimmune hemolytic anemia, to improve diagnostic testing for the development of personalized treatment protocols in AIHA patients

Supportive care

ORASTEM: Oral complications in patients treated with hematopoietic stem cell transplantation

AFFECT-2: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan

CLARITY: Cardiotoxicity and other late effects after radiotherapy and immuno-chemotherapy for non-Hodgkin lymphoma

F2G: An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment options

PLATO: Farmacokinetiek van teicoplanine bij patiënten met een infectie op de intensive care en hematologie afdeling

REDDS2: A randomised feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndrome


PACER: A randomized controlled trial on prophylactic platelet transfusion prior to central venous catheter placement in patients with trombocytopenia

BITE: A nationwide epidemiological and laboratory case cohort study investigating risk factors for bleeding in hemato-oncology patients


PRO-RBDD: Prospective data collection on patients with rare bleeding disorders

RBiN: Rare bleeding disorders in the Netherlands

HemoNED: Landelijk register van patiënten met hemofilie en aanverwante aandoeningen

CoFAB: Coagulation factor deficiencies biobank Maastricht

PRIDES: Observational study on pregnancy outcome in women with inherited bleeding disorders

TAP-100: Validation TAP-100 blood collection device


STARRING: Sickle cell disease: targeting alloantibody formation reduction; risk factors, and genetics

Paroxysmale nachtelijke hemoglobinurie (PNH)

RPNH01: Paroxysmal nocturnal hemoglobinuria (PNH) registry

AK581: Akari long term safety coversin

LNP023: A randomized, multicenter, active-comparator controlled,open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual nemia,despite treatment with an intravenous anti-C5 antibody


Ga terug naar de algemene homepage Studieprotocollen.